These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 33932091)

  • 1. Antinuclear antibodies in COVID 19.
    Muratori P; Lenzi M; Muratori L; Granito A
    Clin Transl Sci; 2021 Sep; 14(5):1627-1628. PubMed ID: 33932091
    [No Abstract]   [Full Text] [Related]  

  • 2. Is COVID-19 severity unrelated to antinuclear antibodies?
    Vahabi M; Mirsharif ES; Ghazanfari T
    Transpl Immunol; 2023 Jun; 78():101791. PubMed ID: 36682573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antinuclear antibodies in COVID-19 patients.
    Beenet L
    J Immunol Methods; 2022 Mar; 502():113215. PubMed ID: 34998816
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms.
    Peluso MJ; Thomas IJ; Munter SE; Deeks SG; Henrich TJ
    Clin Infect Dis; 2022 Jun; 74(11):2083-2084. PubMed ID: 34617982
    [No Abstract]   [Full Text] [Related]  

  • 5. SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.
    Sjöwall J; Azharuddin M; Frodlund M; Zhang Y; Sandner L; Dahle C; Hinkula J; Sjöwall C
    Front Immunol; 2021; 12():724047. PubMed ID: 34512651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.
    Gazzaruso C; Carlo Stella N; Mariani G; Nai C; Coppola A; Naldani D; Gallotti P
    Clin Rheumatol; 2020 Jul; 39(7):2095-2097. PubMed ID: 32462425
    [No Abstract]   [Full Text] [Related]  

  • 7. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures.
    Taeschler P; Cervia C; Zurbuchen Y; Hasler S; Pou C; Tan Z; Adamo S; Raeber ME; Bächli E; Rudiger A; Stüssi-Helbling M; Huber LC; Brodin P; Nilsson J; Probst-Müller E; Boyman O
    Allergy; 2022 Aug; 77(8):2415-2430. PubMed ID: 35364615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
    Bril F; Al Diffalha S; Dean M; Fettig DM
    J Hepatol; 2021 Jul; 75(1):222-224. PubMed ID: 33862041
    [No Abstract]   [Full Text] [Related]  

  • 9. SARS-CoV-2 infection as a trigger of autoimmune response.
    Sacchi MC; Tamiazzo S; Stobbione P; Agatea L; De Gaspari P; Stecca A; Lauritano EC; Roveta A; Tozzoli R; Guaschino R; Bonometti R
    Clin Transl Sci; 2021 May; 14(3):898-907. PubMed ID: 33306235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive Anti-SSA/Ro Antibody in a Woman with SARS-CoV-2 Infection Using Immunophenotyping: A Case Report.
    Huang PI; Lin TC; Liu FC; Ho YJ; Lu JW; Lin TY
    Medicina (Kaunas); 2020 Oct; 56(10):. PubMed ID: 33028028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19.
    Blagova O; Varionchik N; Zaidenov V; Savina P; Sarkisova N
    Eur J Immunol; 2021 Apr; 51(4):893-902. PubMed ID: 33368288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune.
    Timofeeva AM; Sedykh SE; Ermakov EA; Matveev AL; Odegova EI; Sedykh TA; Shcherbakov DN; Merkuleva IA; Volosnikova EA; Nesmeyanova VS; Tikunova NV; Nevinsky GA
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology.
    Mantovani Cardoso E; Hundal J; Feterman D; Magaldi J
    Clin Rheumatol; 2020 Sep; 39(9):2811-2815. PubMed ID: 32720260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild-to-moderate COVID-19 does not predispose to the development of autoimmune rheumatic diseases or autoimmune-based thrombosis.
    Kozłowski P; Lulek M; Skwarek A; Śmiarowski M; Małecka-Giełdowska M; Ciepiela O
    Scand J Immunol; 2023 Nov; 98(5):e13313. PubMed ID: 38441212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies.
    De Santis M; Isailovic N; Motta F; Ricordi C; Ceribelli A; Lanza E; Azzolini E; Badalamenti S; Voza A; Selmi C
    Curr Opin Rheumatol; 2021 Nov; 33(6):514-521. PubMed ID: 34506341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 infection and increasing autoimmune disorders among ICU-hospitalized COVID-19 patients.
    Mosavat A; Mirhosseini A; Shariati A; Mohareri M; Valizadeh N; Mohammadi FS; Shamsian SAA; Jafari Rad M; Rezaee SA
    Int J Rheum Dis; 2023 Nov; 26(11):2151-2156. PubMed ID: 37578135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covid-19 overlapping with systemic sclerosis.
    Mariano RZ; Rio APTD; Reis F
    Rev Soc Bras Med Trop; 2020; 53():e20200450. PubMed ID: 32965452
    [No Abstract]   [Full Text] [Related]  

  • 18. New-onset IgG autoantibodies in hospitalized patients with COVID-19.
    Chang SE; Feng A; Meng W; Apostolidis SA; Mack E; Artandi M; Barman L; Bennett K; Chakraborty S; Chang I; Cheung P; Chinthrajah S; Dhingra S; Do E; Finck A; Gaano A; Geßner R; Giannini HM; Gonzalez J; Greib S; Gündisch M; Hsu AR; Kuo A; Manohar M; Mao R; Neeli I; Neubauer A; Oniyide O; Powell AE; Puri R; Renz H; Schapiro J; Weidenbacher PA; Wittman R; Ahuja N; Chung HR; Jagannathan P; James JA; Kim PS; Meyer NJ; Nadeau KC; Radic M; Robinson WH; Singh U; Wang TT; Wherry EJ; Skevaki C; Luning Prak ET; Utz PJ
    Nat Commun; 2021 Sep; 12(1):5417. PubMed ID: 34521836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
    Fujii H; Tsuji T; Yuba T; Tanaka S; Suga Y; Matsuyama A; Omura A; Shiotsu S; Takumi C; Ono S; Horiguchi M; Hiraoka N
    Clin Rheumatol; 2020 Nov; 39(11):3171-3175. PubMed ID: 32844364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of antinuclear antibodies in patients with COVID-19.
    Cho OH
    Korean J Intern Med; 2023 May; 38(3):280-281. PubMed ID: 37157176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.